Flestolol	flestolol	O	O
:	:	O	O
an	an	O	O
ultra-short-acting	ultra-short-acting	O	O
beta-adrenergic	beta-adrenergic	B_chemicals	O
blocking	blocking	B_chemicals	O
agent	agent	I_chemicals	O
.	.	O	O

Flestolol	flestolol	O	O
(	(	O	O
ACC-9089	acc-9089	O	O
)	)	O	O
is	is	O	O
a	a	O	O
nonselective	nonselective	O	O
,	,	O	O
competitive	competitive	O	O
,	,	O	O
ultra-short-acting	ultra-short-acting	O	O
beta-adrenergic	beta-adrenergic	B_chemicals	O
blocking	blocking	B_chemicals	O
agent	agent	I_chemicals	O
,	,	O	O
without	without	O	O
any	any	O	O
intrinsic	intrinsic	O	O
sympathomimetic	sympathomimetic	S_chemicals	O
activity	activity	O	O
.	.	O	O

Flestolol	flestolol	O	O
is	is	O	O
metabolized	metabolized	O	O
by	by	O	O
plasma	plasma	O	O
esterases	esterases	S_chemicals	O
and	and	O	O
has	has	O	O
an	an	O	O
elimination	elimination	O	O
half-life	half-life	O	O
of	of	O	O
approximately	approximately	O	O
6.5	6.5	O	O
minutes	minutes	O	O
.	.	O	O

This	this	O	O
agent	agent	O	O
was	was	O	O
well	well	O	O
tolerated	tolerated	O	O
in	in	O	O
healthy	healthy	O	O
volunteers	volunteers	O	O
at	at	O	O
doses	doses	O	O
up	up	O	O
to	to	O	O
100	100	O	O
micrograms/kg/min	micrograms/kg/min	O	O
.	.	O	O

In	in	O	O
long-term	long-term	O	O
infusion	infusion	O	O
studies	studies	O	O
,	,	O	O
flestolol	flestolol	O	O
was	was	O	O
well	well	O	O
tolerated	tolerated	O	O
at	at	O	O
the	the	O	O
effective	effective	O	O
beta-blocking	beta-blocking	O	O
dose	dose	O	O
(	(	O	O
5	5	O	O
micrograms/kg/min	micrograms/kg/min	O	O
)	)	O	O
for	for	O	O
up	up	O	O
to	to	O	O
seven	seven	O	O
days	days	O	O
.	.	O	O

Flestolol	flestolol	O	O
blood	blood	O	O
concentrations	concentrations	O	O
increased	increased	O	O
linearly	linearly	O	O
with	with	O	O
increasing	increasing	O	O
dose	dose	O	O
and	and	O	O
good	good	O	O
correlation	correlation	O	O
exists	exists	O	O
between	between	O	O
blood	blood	O	O
concentrations	concentrations	O	O
of	of	O	O
flestolol	flestolol	O	O
and	and	O	O
beta-adrenergic	beta-adrenergic	S_chemicals	O
blockade	blockade	O	O
.	.	O	O

Flestolol	flestolol	O	O
produced	produced	O	O
a	a	O	O
dose-dependent	dose-dependent	O	O
attenuation	attenuation	O	O
of	of	O	O
isoproterenol-induced	isoproterenol-induced	O	O
tachycardia	tachycardia	O	S_disease
.	.	O	O

Electrophysiologic	electrophysiologic	O	O
and	and	O	O
hemodynamic	hemodynamic	O	O
effects	effects	O	O
of	of	O	O
flestolol	flestolol	O	O
are	are	O	O
similar	similar	O	O
to	to	O	O
those	those	O	O
of	of	O	O
other	other	O	O
beta	beta	B_chemicals	O
blockers	blockers	I_chemicals	O
.	.	O	O

In	in	O	O
contrast	contrast	O	O
with	with	O	O
other	other	O	O
beta	beta	B_chemicals	O
blockers	blockers	I_chemicals	O
,	,	O	O
flestolol-induced	flestolol-induced	O	O
effects	effects	O	O
reverse	reverse	O	O
rapidly	rapidly	O	O
(	(	O	O
within	within	O	O
30	30	O	O
minutes	minutes	O	O
)	)	O	O
following	following	O	O
discontinuation	discontinuation	O	O
because	because	O	O
of	of	O	O
its	its	O	O
short	short	O	O
half-life	half-life	O	O
.	.	O	O

Flestolol	flestolol	O	O
effectively	effectively	O	O
reduced	reduced	O	O
heart	heart	O	O
rate	rate	O	O
in	in	O	O
patients	patients	O	O
with	with	O	O
supraventricular	supraventricular	O	S_disease
tachyarrhythmia	tachyarrhythmia	O	S_disease
.	.	O	O

In	in	O	O
patients	patients	O	O
with	with	O	O
unstable	unstable	O	B_disease
angina	angina	O	I_disease
,	,	O	O
flestolol	flestolol	O	O
infusion	infusion	O	O
was	was	O	O
found	found	O	O
to	to	O	O
be	be	O	O
safe	safe	O	O
and	and	O	O
effective	effective	O	O
in	in	O	O
controlling	controlling	O	O
chest	chest	O	B_disease
pain	pain	O	I_disease
.	.	O	O

It	it	O	O
is	is	O	O
concluded	concluded	O	O
that	that	O	O
flestolol	flestolol	O	O
is	is	O	O
a	a	O	O
potent	potent	O	O
,	,	O	O
well-tolerated	well-tolerated	O	O
,	,	O	O
ultra-short-acting	ultra-short-acting	O	O
beta-adrenergic	beta-adrenergic	B_chemicals	O
blocking	blocking	B_chemicals	O
agent	agent	I_chemicals	O
.	.	O	O

Use	use	O	O
of	of	O	O
flestolol	flestolol	O	O
in	in	O	O
the	the	O	O
critical	critical	O	O
care	care	O	O
setting	setting	O	O
is	is	O	O
currently	currently	O	O
undergoing	undergoing	O	O
investigation	investigation	O	O
.	.	O	O

